286 related articles for article (PubMed ID: 34946083)
1. Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources.
Razali R; Asis H; Budiman C
Microorganisms; 2021 Nov; 9(12):. PubMed ID: 34946083
[TBL] [Abstract][Full Text] [Related]
2. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
3. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S
Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510
[TBL] [Abstract][Full Text] [Related]
4. Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
Valipour M
Eur J Med Chem; 2022 Oct; 240():114572. PubMed ID: 35797899
[TBL] [Abstract][Full Text] [Related]
5. Dietary stigmastane-type saponins as promising dual-target directed inhibitors of SARS-CoV-2 proteases: a structure-based screening.
Ogunyemi OM; Gyebi GA; Ibrahim IM; Olaiya CO; Ocheje JO; Fabusiwa MM; Adebayo JO
RSC Adv; 2021 Oct; 11(53):33380-33398. PubMed ID: 35497510
[TBL] [Abstract][Full Text] [Related]
6. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19.
Swargiary A; Mahmud S; Saleh MA
J Biomol Struct Dyn; 2022 Mar; 40(5):2067-2081. PubMed ID: 33089730
[TBL] [Abstract][Full Text] [Related]
7. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
8. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
Anirudhan V; Lee H; Cheng H; Cooper L; Rong L
J Med Virol; 2021 May; 93(5):2722-2734. PubMed ID: 33475167
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances in the Discovery of Potent Proteases Inhibitors Targeting the SARS Coronaviruses.
Sharma A; Kaliya K; Maurya SK
Curr Top Med Chem; 2021; 21(4):307-328. PubMed ID: 33183205
[TBL] [Abstract][Full Text] [Related]
10. Microbial based natural compounds as potential inhibitors for SARS-CoV-2 Papain-like protease (PLpro): a molecular docking and dynamic simulation study.
Rahul S; Sarkar A
J Biomol Struct Dyn; 2022; 40(24):13848-13858. PubMed ID: 34730069
[TBL] [Abstract][Full Text] [Related]
11. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
[TBL] [Abstract][Full Text] [Related]
12.
Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
[TBL] [Abstract][Full Text] [Related]
13. Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development.
Lv Z; Cano KE; Jia L; Drag M; Huang TT; Olsen SK
Front Chem; 2021; 9():819165. PubMed ID: 35186898
[TBL] [Abstract][Full Text] [Related]
14. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
15. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.
Osipiuk J; Azizi SA; Dvorkin S; Endres M; Jedrzejczak R; Jones KA; Kang S; Kathayat RS; Kim Y; Lisnyak VG; Maki SL; Nicolaescu V; Taylor CA; Tesar C; Zhang YA; Zhou Z; Randall G; Michalska K; Snyder SA; Dickinson BC; Joachimiak A
Nat Commun; 2021 Feb; 12(1):743. PubMed ID: 33531496
[TBL] [Abstract][Full Text] [Related]
16. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
Amin SA; Banerjee S; Gayen S; Jha T
Eur J Med Chem; 2021 Apr; 215():113294. PubMed ID: 33618158
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
18. Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease.
Liu W; Wang J; Wang S; Yue K; Hu Y; Liu X; Wang L; Wan S; Xu X
Bioorg Chem; 2023 Nov; 140():106830. PubMed ID: 37683544
[TBL] [Abstract][Full Text] [Related]
19. A chimeric virus-mouse model system for evaluating the function and inhibition of papain-like proteases of emerging coronaviruses.
Deng X; Agnihothram S; Mielech AM; Nichols DB; Wilson MW; StJohn SE; Larsen SD; Mesecar AD; Lenschow DJ; Baric RS; Baker SC
J Virol; 2014 Oct; 88(20):11825-33. PubMed ID: 25100850
[TBL] [Abstract][Full Text] [Related]
20. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
